NDA 212489 · Amneal
Ongentys
Opicapone · Oral · Catechol-O-Methyltransferase Inhibitor
NovelLast checked: Nov 19, 2026Latest source record: Oct 10, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Apr 24, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
46
4 Phase 3, 0 recruiting
FAERS reports
2,446
1,874 serious, 250 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 4, 2025.
ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. ONGENTYS is a catechol-O-methyltransferase (COMT) inhibitor indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes. ( 1 )
Mechanism: Opicapone is a selective and reversible inhibitor of catechol-O-methyltransferase (COMT). COMT catalyzes the transfer of the methyl group of S-adenosyl-L-methionine to the phenolic group of substrates that contain a catechol structure. Physiological substrates of COMT include DOPA, catecholamines (dopamine, norepinephrine, and epinephrine), and their hydroxylated metabolites. When decarboxylation of levodopa is prevented by carbidopa, COMT becomes the major metabolizing enzyme for levodopa, catalyzing its metabolism to 3-methoxy-4-hydroxy-L-phenylalanine (3-OMD).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- ONGENTYS · OPICAPONE 50MG · CAPSULE, ORAL · Prescription
- ONGENTYS · OPICAPONE 25MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Opicapone" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients With "Wearing-off" PhenomenonPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01568073 · 600 participants · Start Mar 2011 · Primary completion Nov 2013
Drug: BIA 9-1067; Entacapone and 4 more · For: Parkinson's Disease
Sites: S. Mamede Do Coronado, Portugal
Bial - Portela C S.A.Industry
NCT02847442 · 518 participants · Start Nov 23, 2016 · Primary completion Jul 4, 2018
Drug: BIA 9-1067; levodopa/dopa decarboxylase inhibitor · For: Parkinson's Disease With Wearing-off Motor Fluctuations
Sites: Dresden, Germany
- Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.Pivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01227655 · 427 participants · Start Mar 2011 · Primary completion Jul 2012
Drug: BIA 9-1067; Placebo and 3 more · For: Parkinson's Disease
Sites: S. Mamede Do Coronado, Portugal
- Early ParkinSon wIth L-DOPA/DDCI and OpicapoNe (EPSILON Study)Pivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT04978597 · 410 participants · Start May 31, 2021 · Primary completion Jan 11, 2023
Drug: Opicapone 50 mg; Placebo · For: Parkinson
Sites: Dupnitsa, Bulgaria
- A Study to Evaluate the add-on Efficacy and Safety of Opicapone 50 mg or an Extra Dose of L-DOPA 100 mg for the Treatment of Wearing-off in Patients With PDPivotal-lookingCompleted
SK Chemicals Co., Ltd.Industry
NCT04821687 · 169 participants · Start Jun 17, 2021 · Primary completion Aug 18, 2022
Drug: Ongentys 50mg; Madopar Tab. 125 or Perkin Tab. 25-100mg · For: Parkinson Disease
Sites: Anyang-si, South Korea
- OpiCapone Effect on Motor Fluctuations and pAiNPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT04986982 · 144 participants · Start Feb 25, 2021 · Primary completion Feb 16, 2024
Drug: Opicapone 50 mg · For: Parkinson Disease
Sites: London, United Kingdom
- eArly levoDopa With Opicapone in Parkinson's paTients wIth motOr fluctuatioNs.Pivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT04990284 · 106 participants · Start Nov 29, 2021 · Primary completion Apr 4, 2023
Drug: Opicapone; L-DOPA/DDCI · For: Parkinson Disease
Sites: Freiburg im Breisgau, Germany; Wolfach, Germany; Haag in Oberbayern, Germany · 25 sites in all
- Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian SubjectsPivotal-lookingCompleted
Bial - Portela C S.A.Industry
NCT01520987 · 105 participants · Start May 2011 · Primary completion Nov 2012
Drug: BIA 9-1067; Placebo · For: Parkinson Disease
Sites: Honolulu, Hawaii
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hallucination339
- dyskinesia338
- fall291
- on and off phenomenon196
- tremor163
- death150
- gait disturbance143
- drug ineffective134
- confusional state130
- parkinson^s disease127
- fatigue119
- hallucination, visual116
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 21 |
| 2018 | 40 |
| 2019 | 61 |
| 2020 | 177 |
| 2021 | 567 |
| 2022 | 277 |
| 2023 | 243 |
| 2024 | 258 |
| 2025 | 358 |
| 2026 | 443 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ongentys (Opicapone)
2024 spending
$15.4M
Beneficiaries
3,276
16,686 claims
Per beneficiary
$4,687
$21.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $545,253 |
| 2021 | $6,710,087 |
| 2022 | $11,855,741 |
| 2023 | $15,941,380 |
| 2024 | $15,354,274 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Opicapone for Parkinson's disease-related sleep disturbances: The OASIS clinical trial.
Ferreira JJ, Gago MF, Costa R, et al. · J Parkinsons Dis 2025 · Clinical Trial, Research Support, Non-U.S. Gov't
- Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
Ferreira JJ, Lees A, Rocha JF, et al. · Lancet Neurol 2016 · Multicenter Study, Randomized Controlled Trial
- Opicapone as adjunct to levodopa in treated Parkinson's disease without motor complications: A randomized clinical trial.
Ferreira JJ, Rascol O, Stocchi F, et al. · Eur J Neurol 2025 · Clinical Trial, Phase III, Multicenter Study
- How to Optimize the Effectiveness and Safety of Parkinson's Disease Therapy? - A Systematic Review of Drugs Interactions with Food and Dietary Supplements.
Agnieszka W, Pawe P, Magorzata K · Curr Neuropharmacol 2022 · Systematic Review
- Safety Profile of Opicapone in the Management of Parkinson's Disease.
Lees A, Ferreira JJ, Rocha JF, et al. · J Parkinsons Dis 2019 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Long-term follow up of opicapone as add-on to levodopa in Parkinson's patients without motor fluctuations.
Ferreira JJ, Rascol O, Stocchi F, et al. · J Parkinsons Dis 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
Sponsor: Amneal
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.